Kezar Life Sciences

93 articles about Kezar Life Sciences

• Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

  5/11/2023

  Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update.

• Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 05, 2023

  4/5/2023

  Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted six employees nonqualified stock options to purchase 232,000 shares of its common stock with an exercise price of $3.05 per share, which is equal to the closing price of Kezar’s common stock on April 3, 2023, the grant date of the awards.

• Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

  3/14/2023

  Kezar Life Sciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

• Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

  3/13/2023

  Kezar Life Sciences, Inc. today announced that the Company will pull forward its virtual Research and Development Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT.

• Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

  3/6/2023

  Kezar Life Sciences, Inc. today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT.

• Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 03, 2023

  3/3/2023

  Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase 33,000 shares of its common stock with an exercise price of $5.43 per share, which is equal to the closing price of Kezar’s common stock on March 2, 2023, the grant date of the awards.

• Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

  3/1/2023

  Kezar Life Sciences, Inc. announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Autoimmune/Complement/Inflammation panel discussion at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 am ET in Boston, MA.

• Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 06, 2023

  2/6/2023

  Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted five employees nonqualified stock options to purchase 131,000 shares of its common stock with an exercise price of $7.10 per share, which is equal to the closing price of Kezar’s common stock on February 3, 2023, the grant date of the awards.

• Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  1/13/2023

  Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 65,000 shares of its common stock with an exercise price of $6.84 per share, which is equal to the closing price of Kezar’s common stock on January 6, 2023, the grant date of the awards.

• Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 pm PT in San Francisco, CA.

• Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - December 07, 2022

  12/7/2022

  Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase 65,500 shares of its common stock with an exercise price of $7.07 per share, which is equal to the closing price of Kezar’s common stock on December 5, 2022, the grant date of the awards.

• Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

  11/14/2022

  Kezar Life Sciences, Inc. today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib in active lupus nephritis (LN) at the American College of Rheumatology (ACR) Convergence 2022 in Philadelphia, PA.

• Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - November 11, 2022

  11/11/2022

  Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 30,000 shares of its common stock with an exercise price of $7.06 per share, which is equal to the closing price of Kezar’s common stock on November 7, 2022, the grant date of the award.

• Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

• Kezar Life Sciences to Participate in Two Upcoming November 2022 Investor Conferences

  11/9/2022

  Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced members of the executive team will participate in two upcoming investor conferences in November.

• Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting

  11/3/2022

  Kezar Life Sciences, Inc. (Nasdaq: KZR) today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class, selective immunoproteasome inhibitor, in active lupus nephritis (LN) at the American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting in Orlando, FL.

• Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting

  10/14/2022

  Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting.

• Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - October 06, 2022

  10/6/2022

  Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase 85,000 shares of its common stock with an exercise price of $8.80 per share, which is equal to the closing price of Kezar’s common stock on October 3, 2022, the grant date of the awards.

• Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

  10/3/2022

  Kezar Life Sciences, Inc. announced that it has received clearance of its Investigational New Drug application from the U.S. Food and Drug Administration for zetomipzomib, its first-in-class, selective immunoproteasome inhibitor, for the treatment of autoimmune hepatitis.

• Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022

  9/29/2022

  Kezar Life Sciences, Inc. announced that three posters will be presented at the upcoming American College of Rheumatology Convergence 2022, which will take place November 10 – 14, 2022 in Philadelphia, PA.